Lanreotide (CAS 108736-35-2) – Wholesale & Research Grade
Lanreotide, a synthetic analogue of somatostatin, is widely recognized for its therapeutic applications in treating neuroendocrine tumors, acromegaly, and other hormone-related disorders. Its ability to inhibit the secretion of various hormones makes it a valuable compound in both clinical and research settings.
Research Applications
Lanreotide is primarily utilized in the management of conditions characterized by excessive hormone production, such as acromegaly, where it aids in normalizing growth hormone levels. Additionally, it is employed in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), providing symptomatic relief and improving patient quality of life. The compound is also being investigated for potential applications in other areas, including the treatment of certain types of pain syndromes and conditions associated with insulin dysregulation.
Mechanism of Action
The mechanism of action of lanreotide is centered around its affinity for somatostatin receptors, particularly subtype 2 and 5. By binding to these receptors, lanreotide effectively inhibits the secretion of growth hormone and other hormones such as insulin and glucagon. This action not only helps in controlling hypersecretion disorders but also demonstrates anti-proliferative effects on tumor cells, making it a critical focus for ongoing cancer research.
Solubility and Storage Advice
Lanreotide is soluble in water, facilitating its use in various formulations for parenteral administration. For optimal stability, it should be stored in a refrigerator at temperatures between 2°C and 8°C, protected from light. Proper storage conditions are crucial to maintaining the integrity of this compound, ensuring its efficacy in therapeutic and research applications.
Future Research Directions
Looking ahead, research is poised to explore the full potential of lanreotide in combination therapies, particularly its synergistic effects with other anticancer agents. Additionally, investigations into its role in new therapeutic areas, such as metabolic disorders and targeted drug delivery systems, are gaining momentum. As a potent somatostatin analogue, lanreotide continues to hold promise for advancing treatment strategies across a spectrum of endocrine-related diseases.
| CAS Number | 108736-35-2 |
|---|---|
| Formula | C54H69N11O10S2 |
| Mol. Weight | 1096.3 g/mol |
| IUPAC Name | (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxob... |
| Grade | HPLC ≥98% |
Synthesis & Storage
Lanreotide is supplied as a lyophilized powder to ensure stability during transit.
For long-term storage of CAS 108736-35-2, we recommend maintaining at -20°C.
Researchers must reconstitute this peptide with bacteriostatic water or sterile solvent only when ready for use.
Quality Control: All batches undergo rigorous HPLC purity testing (≥98%) prior to dispatch from our USA fulfillment center.